OptiNose Reveals Bi-directional Nasal Device Phase II Results
OptiNose, a provider of bi-directional nasal activity technology, has released positive Phase II trial results evaluating the bi-directional nasal device delivering fluticasone, a nasal steroid, which demonstrated to be effective in progressively reducing the size or eliminating nasal polyps in patients with chronic rhinosinustis (CRS) with nasal polyps.
OptiNose Phase II study results also showed that the drug delivery technology was equally effective in treating patients with newly diagnosed and those with recurring nasal polyps post sinus surgery.
OptiNose said that the clinical results achieved offered an opportunity for analysis for subgroups with different baseline polyp size.
Per Djupesland, chief scientific officer of OptiNose and inventor of the company's bi-directional delivery technology, said: "We are excited by study results that suggest our bi-directional drug delivery technology delivers a progressive treatment effect on nasal polyps of all sizes, leading to notable reduction and even complete resolution of polyps.
"Progressive reduction of all sized polyps is critical for successful treatment because large polyps become small polyps and then are eliminated. We were also pleased to see that our treatment is as efficient in the patients with recurring polyps following sinus surgery as in patients without prior surgery."
James Palmer, associate professor, director of the division of rhinology, department of otorhinolaryngology and head and neck surgery at the University of Pennsylvania, said: "These study results suggest greater efficacy in treating nasal polyps than existing methods and with further validation may be a means to avoid sinus surgery in certain cases."
Peter Miller, CEO of OptiNose, said: "We are encouraged by our findings across the Phase II clinical trials and particularly by the data represented in this subgroup analysis.
"We are now focusing on structuring a Phase III program towards conclusively demonstrating better efficacy of OptiNose's products for the treatment of both chronic rhinosinusitis with nasal polyps and for migraines."
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.